ClinicalTrials.gg
Active, not recruitingNCT05019664Updated Sep 25, 2026

Affixus Natural Nail System Humeral Nail PMCF

An observational study in Humeral Fractures, Proximal and Humeral Fractures, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Zimmer Biomet · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Shoulder Fractures by Zimmer Biomet — 7 open to participants now, 9 under way, none of them phase 3. Shoulder Fractures · Zimmer Biomet.

Planned enrollment
3rd of 10
100 · median 69
Started
2022
with 2 others
Observational
10 of 12
6 open now
Registered
5th of 12
by date

Among the 12 studies in Shoulder Fractures by Zimmer Biomet, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 5th registered.

Shoulder Fractures

113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.

Browse Shoulder Fractures studies →

Open to participants now

7 of the 12 studies in Shoulder Fractures by Zimmer Biomet are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 18 Shoulder Fractures studies recruiting now, 13 (72%) set no upper age limit and 3 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Shoulder Fractures by Zimmer Biomet, or all of them as a file.
02

Study summary

A commercially available product clinical study which aims to confirm the safety, performance and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone nail system for both the implant itself and the instrumentation used during surgery.

Read the detailed description

Study objective:

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the Affixus Natural Nail System Humeral Nail and its instrumentation by analyzing adverse event records, fracture/osteotomy healing and functional outcome and adverse events.

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.

The performance and clinical benefits will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

Study Endpoints:

Primary endpoint:

The primary endpoint is bone union after 12 months since surgery.

Secondary endpoint:

The secondary endpoints will be evaluating functional outcomes (Range of Motion, \& American Shoulder and Elbow Surgeons questionnaire), quality of life questionnaire (EQ-5D-5L), radiographic findings and adverse events including re-operation of all enrolled study subjects at the defined follow up time points.

03

Conditions studied

  • Humeral Fractures, Proximal
  • Humeral Fractures
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive series of 100 subjects globally implanted with the Affixus Natural Nail System Humeral Nail for temporary fixation and stabilization of fractures or osteotomies of the humerus.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older and skeletally mature.
  • Patient must have either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.
  • Patient has been or is scheduled to be treated with the Affixus Natural Nail System Humeral Nail.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must have a signed Institutional Review Board/Ethics Committee approved . (An Institutional Review Board/Ethics Committee is group that has been formally designated to review and monitor medical research involving human subjects.)
  • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study.

Exclusion criteria

Exclusion Criteria:

  • Distal fracture involving the olecranon fossa.
  • Bone shaft having excessive bow or deformity.
  • A medullary canal obliterated by a previous fracture or tumor.
  • Active or previous infection.
  • Skeletally immature patients.
  • All concomitant diseases that can impair the functioning and the success of the implant.
  • Patients with mental or neurologic conditions who are unwilling or incapable of giving proper and following postoperative care instructions.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
  • Patient known to be pregnant or breast feeding.
  • Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study).
  • Patients who have any condition that would in the judgment of the investigator place the patient at undue risk or interfere with the study.
  • Not expected to survive the duration of the follow-up program.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Devicehumeral fracture

    Patient with either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.

06

What researchers measure

Primary outcomes

  1. Bone Union

    The primary endpoint is bone union after 12 months since surgery. (Bone union defined as no pain or tenderness at the site, and strong enough to allow normal activities.)

    Time frame: 12 months

Secondary outcomes

  1. Range of Motion

    The Range of Motion (total shoulder motion, active and passive) of the affected and contralateral (right and left) upper arm will be measured.

    Time frame: 12 months

  2. EQ-5D-5L

    EQ-5D-5L Health Questionnaire is completed by the patient and assesses his/her general health status. The EQ-5D-5L is used to derive a quality of life index used for health economics considerations.

    Time frame: 12 months

  3. Radiographic Findings

    Postoperative Radiographic Evaluation collects radiographic parameters like bridging callus, visible fracture line, device fracture, device loosening and union status (AP, lateral, and auxiliary view).

    Time frame: 12 months

  4. Adverse Events

    Adverse Event Report is completed as needed for each complication which is noted.

    Time frame: 12 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Undecided — This aspect of the study is undecided.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.

Of 30 observational studies under Shoulder Fractures, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 109. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Aug 25, 2021
StartActual
Aug 29, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05019664
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Aug 25, 2021
Start date
Aug 29, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Emilie Rohmer, MSc.
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion